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INTRODUCTION
Idiopathic eosinophilic pneumonia (IEP) is charac-
terized by the accumulation of eosinophils in the al-
veolar spaces and the interstitium of the lungwith un-
known etiology, frequently accompanied by peripheral
eosinophilia (1, 2). Previous studieshavedemonstrated
that eosinophils play a critical role in the lung injury of
IEP by releasing toxic granule proteins includingmajor
basic protein (MBP), eosinophilic cationicprotein (ECP)
and eosinophil peroxidase (EPO)(2, 3). However, the
pathogenesis of IEP still remains unclear.
Much attention has focused on themechanisms in-
volved in the accumulation of eosinophils in the lung.
Since interleukin (IL)-5 has the capacity to attract and
activate eosinophils (4, 5), it has beenconsidered to play
a role in the recruitment of eosinophils to the site of
inflammation in the lung of IEP patients. In fact, IL-5
has been reported to be elevated in bronchoalveolar
lavage fluid (BALF) of IEP patients (6, 7). Furthermore,
eotaxin, a selective CC chemokine for eosinophils, has
been demonstrated to be essential for the accumulation
of eosinophils in the lung using anallergic inflammation
model (8, 9). Recent reports demonstrated that eotaxin
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was also elevated inBALFof IEP (10, 11). These results
suggested that IL-5 and eotaxin might play a critical
role in the recruitment of eosinophils in the lung of
IEP patients.
Recently, CD4+ T lymphocytes were divided into two
subgroups on the basis of their cytokine production.
T helper (Th)1 cells produce IL-2, interferon (IFN)-γ
and tumor necrosis factor (TNF)-β andmediate cellular
immune responses, whereas Th2 cells secrete IL-4,
IL-5 and IL-6 and promote the humoral immune re-
sponses (12). The chemokine receptors specifically
expressed on Th1or Th2 cells were also identified,
and it was found that Th1 cells are recognized by the
expression of CCR5 or CXCR3, and Th2 cells by CCR4
(13). AlthoughTh1/Th2 balance in IEP is still unclear,
it is likely that Th2 cells play a role in the pathogenesis
of IEP since IL-5 was elevated in BALF of IEP.Recently,
Miyazaki et al. reported that thymus-and activation-
regulated chemokine (TARC), which is a ligand for the
CCR4 chemokine receptor, contributed the recruit-
ment of Th2 lymphocytes to the lung in patients with
IEP(14).
In the present study, we examined the level of
macrophage-derived chemokine (MDC), which is an-
other ligand for the CCR4 chemokine receptor, inBALF
from patients with IEP or other interstitial lung diseases
(ILDs). Furthermore, we examined the production of
MDC by alveolar macrophages (AM) derived from
BALF of patients with IEP.
MATERIALS AND METHODS
Subjects
Studies were performed in 18 patientswith IEP, 8 pa-
tients with idiopathic pulmonary fibrosis (IPF), 8 patients
with cryptogenic organizing pneumonia (COP)/bron-
chiolitis obliterance organizing pneumonia (BOOP),
8 patients with sarcoidosis, 8 patients with hypersensi-
tivity pneumonitis (HP) and 7 healthy volunteers (HV)
(table 1). IEP was diagnosed by clinical criteria as fol-
lows : 1) no known cause of EP such as drug allergy or
parasitic and fungal infections ; 2) alveolar, interstitial
or mixed opacity on chest roentgenograms ; 3) an in-
creased number of eosinophils in BALF and the al-
veolar spaces and septa by transbronchial lung biopsy
(TBLB) ; 4) prompt resolution with or without corti-
costeroid therapy (1). IPF was diagnosed according
to the International Consensus Statement (15). The
diagnosis ofCOP/BOOPwasbasedon clinicopathologi-
cal evaluation as follows ; 1) subacute onset ; 2) alveo-
lar opacity on chest roentgenogram andCT ; 3) no evi-
dence of infectious or collagen vascular diseases which
might cause COP;4) typical histologic patternbyTBLB;
5) rapid responses to corticosteroid therapy (15). Sar-
coidosis was diagnosed by previously described clinical
and histologic criteria (16). The diagnosis of HP was
performed on the basis of the previously described
criteria (17).
None of the patients were receiving corticosteroid
therapy at the time of the investigation. Two patients
with IEP had a past history of symptomatic bronchial
asthma (BA), whereas none of the patients with other
ILDs and healthy volunteers had atopic status. Three
IEP patients received a second BAL after clinical re-
mission with or without corticosteroid therapy.
Bronchoalveolar lavage
The study was performed under the ethical guide-
line of the University of Tokushima and the written
informed consent was obtained from the subjects.BAL
was performed as described previously (18). Briefly,
a flexible fiberoptic bronchoscope (Model 1T20 ; Olym-
pus Co., Tokyo, Japan) was wedged into a segmental
or subsegmental bronchus of the middle lobe or lin-
gual, and lavage was performed with a total volume
of 150 ml of sterile 0.9% saline warmed at 37℃ in three
50-ml aliquots. The lavage fluid was gently aspirated
by syringe after deep inspiration. The fluid recovered
was passed through a sterile gauze and centrifuged
at 250 x g for 10 min at 4℃ to precipitate cells, and the
supernatants were stored at -70℃ until examination.
The total number of cells was counted using the trypan-
blue dye exclusion test. Differential counts on 400 cells
were carried out on smears of sedimentedcells stained
with Diff-Quik stain (Baxter Dade AG, Duedingen,
Switzerland)(19).
Measurement of MDC and TARC
The frozenBALFwas quickly thawedandused to ex-
amine the concentration of MDC and TARCby ELISA
(R&D system,Minneapolis,MN,USA). The procedure
was performed as described in the manufacturer’s in-
structions (20). The minimal detectable level of MDC
and TARC was 62.5 and 7 pg/ml, respectively.
Harvesting of the supernatant of AM
The total cells in BALF were added to a 96-well flat-
bottom plate at 1×105AM per well. After incubation
at 37℃ for 1 h, these cells were washed three times
with cold phosphate-buffered saline (PBS)(-) to remove
the non-adherent cells. The purity of AM at this point
was more than 90%, as judged by the stainingwith Diff-
Quik stain. AMwere subsequently cultured in RPMI
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1640 supplemented with 10% heat-inactivated fetal
bovine serum (FBS ; GIBCO, Grand Island, NY, USA).
Their supernatants were harvested after culture for
24 and 48 hrs.
Preparation of total RNA of AM
Total RNAwas isolated fromAMusing Isogen (Wako
K.K., Kyoto, Japan). Briefly, BAL cells were added to
a 10 cm-dish with RPMI 1640 supplemented with 10%
FBS. After incubation at 37℃ for 1 h, these cells were
washed three times with cold PBS (-) to remove the
non-adherent cells. One milliliter of Isogen was added
to the remaining cells, and then thecellswereharvested
using a cell-scraper (SUMITOMO BAKELITE CO.,
LTD., Tokyo, Japan) to an eppendorf tube. Total RNA
was extracted according to themanufacturer’s instruc-
tions (21).
Real-time quantitative PCR analysis for MDC
Ten nanograms of total RNA was used for RT-PCR
using a One step real-time PCR Kit (Applied Biosys-
tems, Foster City, CA, USA). Real-time quantitative
PCR was performed in the ABI prism 7700 Sequence
detector (Applied Biosystems). The primer and probe
for humanMDCwere designed based on the published
sequence data (22), and are as follows :MDC forward
primer, 5’-TGCCGTGATTACGTCCGTTAC-3’; MDC
reverse primer, 5’-ATCGGCACAGATCTCCTTATCC-
3’ ; MDC TaqMan probe, 5’-FAM-CGCGTGGTGA
AACACTTCTACTGGACCTC-TAMRA-3’. Each RT-
PCR reaction was performed in duplicate wells using
a TaqManOne-step RT-PCRMasterMix Reagents Kit
(Applied Biosystems).TheRTreactionwasperformed
at 48℃ for 30 min and 95℃ for 10 min. PCR was per-
formed for 40 cycles at 95℃ for 15 sec and 60℃ for 1
min. Real-time RT-PCR for β-actin was also performed
as a control using a TaqMan β-actin Control Reagents
(Applied Biosystems) under the same conditions as
for MDC. The relative expression of MDCmRNAwas
calculated as the value of MDC mRNA/the value of
β-actin.
Statistical analysis
Statistical analysis was performed using the unpaired
two-tailed Student’s t test. Correlation coefficients were
determined using the Pearson’s linear regressionanaly-
sis. Statistical analysis was performed with StatView
software. Differenceswere considered significant when
p values were less than 0.05.
RESULTS
Characteristics of BALF of patients with various ILDs
The characteristics of BALF of patients with various
ILDs are shown in Table 1. The total number of cells
in BALF of patients with IEP, sarcoidosis andHPwas
significantly higher than that of HV. The percentage of
lymphocytes was significantly increased in the COP,
sarcoidosis and HP groups, and that of eosinophils was
higher in IEP and COP when compared with HV.
The concentration of MDC and TARC in BALF of
patients with various ILDs
We examined the level of MDC and TARC inBALF
of patients with various ILDs using ELISA. The results
are shown in figure 1. MDC in BALF was detected in
thirteen of eighteen IEP patients (72%)(Fig. 1a). TARC
was also detected in nine of eighteen IEP patients (50%)
(Fig. 1b). However, neither MDC nor TARC was de-
Table 1. Characteristics of study populations
Bronchoalveolar lavage
Total cells Percentages of total cells
Group male/female Age (yr) (x 105/ml) AM Ly Neut Eo
IEP 9/9 48.0±4.2 10.1±2.3＊ 25.9±3.8# 21.1±5.3 3.2±1.4 49.8±5.7#
IPF 7/1 67.1±1.7 3.2±1.0 66.4±8.3† 21.3±4.7 5.8±3.1 6.5±3.1
COP 3/5 51.7±5.1 6.2±2.3 50.7±6.9# 41.5±7.0＊ 3.4±1.7 4.4±1.3†
SAR 3/5 47.0±4.9 3.9±0.6† 48.3±6.5# 50.6±6.6# 0.7±0.3 0.6±0.3
HP 4/4 54.4±3.1 9.2±2.0§ 39.3±7.8# 56.0±8.4# 1.5±0.5 3.3±1.5
HV 6/1 21.9±0.8 2.0±0.2 88.9±2.6 10.0±2.5 0.7±0.2 0.3±0.2
Data are shown as Mean±SEM. ＊P＜0.005, compared with the group of HV ; #P＜0.001, compared with the group of HV;
†P＜0.05, compared with the group of HV ;§P＜0.01, compared with the group of HV. AM : alveolar macrophages ; COP :
cryptogenic organizing pneumonia ; Eo : eosinophils ; IEP : idiopathic eosinophilic pneumonia ; HP : hypersensitivity
pneumonitis ; HV : healthy volunteers ; IPF : idiopathic pulmonary fibrosis ; Ly : lymphocytes ; Neut : neutrophils ; SAR :
sarcoidosis.
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tected in BALF of HV or patients with other ILDs in-
cluding IPF, COP, sarcoidosis andHP. In three patients
in the IEP group who were complicated with symp-
tomatic BA, one patient did not show an elevation of
either MDC or TARC.
Comparison of the level of MDC and TARC in BALF
of patients with IEP
We next compared the level of MDC and TARC in
BALF of patients with IEP. As shown in Fig. 2a, the
concentration of MDC was significantly higher than
that of TARC (Mean±SEM ; 1819±371 versus 176±
63 pg/ml, p<0.001). In all patients, MDC was consis-
tently higher than TARC. On the other hand, the level
Fig. 1. Concentration of macrophage-derived chemokine (MDC)
and thymus-and activation-regulated chemokine (TARC) in bron-
choalveolar lavage fluid (BALF). The BALF obtained from healthy
volunteers (HV) or patients with various interstitial lung diseases
was used for themeasurement of a)MDC ; andb)TARCwithELISA.
Each closed circle indicates an individual specimen andopen circles
are the data from symptomatic asthmatic patients. Bars are mean±
SEM of all values. A value of 62.5 or 7 pg/mlwasgiven to all samples
that read out below the level of detection in the ELISA for MDC
or TARC, respectively. COP : cryptogenic organizing pneumonia,
IEP : idiopathic eosinophilic pneumonia, HP: hypersensitivity pneu-
monitis, IPF : idiopathic pulmonary fibrosis, SAR : sarcoidosis.
Fig. 2. Correlation between the level of macrophage-derived
chemokine (MDC) and thymus-and activation-regulated chemokine
(TARC) in patients with idiopathic eosinophilic pneumonia (IEP).
a) Comparison of the level ofMDC and TARC in patients with IEP.
Each closed circle indicates an individual patient. Bars are mean±
SEM of all values (n=13). The level ofMDCwas significantly higher
than that of TARC (p <0.001) ; b) Correlation between the level of
MDC and TARC in patients with IEP. The level ofMDC correlated
with that of TARC (r=0.62, p<0.05). A value of 7 pg/ml was given
to all samples that read out below the level of detection in theELISA
for TARC.
Fig. 3. Production of macrophage-derived chemokine (MDC)
by alveolar macrophages (AM) harvested from healthy volunteers
(HV) or patients with idiopathic eosinophilic pneumonia (IEP).
AM were cultured without stimulation for 24 and 48 hrs. The su-
pernatants were harvested, and the concentration ofMDCwasmeas-
ured with ELISA. Data are shown as mean±SD of threeHV (open
column) or patients with IEP (shaded column).
Fig. 4. Expression of mRNA of macrophage-derived chemokine
(MDC) in alveolar macrophages (AM) from patients with idiopathic
eosinophilic pneumonia (IEP). Total RNA was extracted from AM
in healthy volunteers (HV) or patientswith IEP. The real-time quan-
titative RT-PCR forMDCwas performed as described inMethods.
Each column indicates the data from an individual subject.
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of MDC in BALF of patients with IEP correlated with
that of TARC (r=0.62, p<0.05)(Fig. 2b).Wealsoanalyzed
the correlation between the level ofMDCor TARC and
the number of lymphocytes or eosinophils in BALF,
and found that there was no correlation between these
factors (data not shown).
Increased production of MDC by AM from patients
with IEP
Recently, Fahy et al. reported that human AM har-
vested from asthmatic patients could produce MDC
(23). We therefore examined the production of MDC
by AM harvested from HV and patients with IEP. AM
harvested from IEP had the ability to spontaneously
produce a higher amount ofMDCwhen comparedwith
that of HV (Fig. 3). Furthermore, we analyzed the ex-
pression ofMDCmRNAusing a real-time quantitative
RT-PCR. As shown in Fig. 4, AM from three patients
with IEP also expressed a higher amountofMDC tran-
script at the mRNA level when compared with that of
HV.
Clinical relevance of MDC level in BALF of patients
with IEP
Three patients with active IEP received a second
BAL when the clinical symptoms and signs of active
IEP improved spontaneously or after a therapy with
corticosteroids. The level of MDC or TARC in BALF
declined in parallel with a reduction in the number
of total cells and eosinophils in BALF (Table 2).
DISCUSSION
In the present study, we demonstrated that the con-
centrations ofMDCandTARC inBALF of patientswith
IEP were significantly higher than those of HV or pa-
tients with other ILDs. Furthermore, when the produc-
tion of MDC by AM at the protein and mRNA levels
was examined, AM harvested from patients with IEP
showed the higher production of MDC than HV.
Recently,Miyazaki et al. reported that TARC inBALF
of patients with EP was significantly higher than that
of HV or patients with other ILDs such as HP, sarcoi-
dosis and IPF (14).MDC recognizesCCR4, a receptor
that is shared by TARC (24). Therefore, it could be of
importance to examinewhetherMDCor TARC plays
a more critical role in the pathogenesis of IEP. In the
present study, we demonstrated that MDC aswell as
TARC was elevated in BALF of patients with IEP.These
data are consistent with the results recently reported
by Katoh et al., in which they demonstrated that both
MDC and TARC were elevated in BALF of IEP (25).
They also reported that the concentrations of MDC
and TARCwere correlatedwithCCR4＋ T cells in BALF
of patients with IEP. However, they did not examine
COP and HP patients, and the source of MDC in the
lung of IEP. Therefore, we further analyzed theMDC
level in BALF of patients with various ILDs and the
production of MDC by AM in IEP.
The level ofMDCwas significantly higher than that of
TARC inall IEPpatients.Thesedata, togetherwithareport
that the chemotactic activity ofMDC for CCR4-positive
cells was higher than that of TARC at the same concen-
tration (24), strongly suggest that MDC, in addition to
TARC, could be a major chemoattractant for Th2-type
cells in the lung of IEP. However,MDC-producing cells
are different from those that produce TARC in the lung ;
the former beingmacrophagesand the latter endothelial
and bronchial epithelial cells (27, 28). In fact, whenwe
Table 2. Decreased level of macrophage-derived chemokine in bronchoalveolar lavage fluid from patients with idiopathic eosinophilic
pneumonia after clinical remission＊
Bronchoalveolar lavage








1 active 4.2 36.8 2999 13.5
remission 2.1 2.0 72 ＜7
2 active 37.5 89.2 2325 ＜7
remission 5.9 3.6 ＜62.5 ＜7
3 active 7.6 45.0 3973 785
remission 6.1 16.0 ＜62.5 ＜7
＊Case 1 and 3 were treated by oral administration with 0.5 mg/kg of prednisolone for one month and then corticosteroids were
tapered. When the pulmonary infiltrates on chest radiographs improved, a second BAL was performed. Case 2 showed spon-
taneous improvement. This patient also received a second BAL after clinical remission. MDC: macrophage-derived chemokine,
TARC : thymus-and activation-regulated chemokine.
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examined the production of TARC fromAM, the level
of TARC in the supernatant was undetectable or neg-
ligible in all cases (data not shown). These resultswere
consistent with the previous reports showing that both
murine and humanmacrophages did not expressTARC
even at themRNA level (29, 30).On theotherhand,we
observed a positive correlation between theMDC and
TARC level in BALF of patients with IEP, implying that
the production and function of these chemokines is
likely to be cooperatively regulated. Furthermore, both
MDC andTARCwere rapidly reducedwhen the disease
activity of IEPwas improved. These data suggests that
bothMDCandTARCwere strictly related to the clinical
status of IEP.
Themajor source ofMDC is reported to bemonocyte-
derived macrophages and dendritic cells (28). However,
it has been unknown whether human tissue macro-
phages could produce MDC. Fahy et al. recently re-
ported that human AM harvested from asthmatic pa-
tients could produceMDC in response todiesel exhaust
particle (DEP)(23). They also demonstrated that AM
produced a significant amount of MDC without any
stimulation, although they did not compareMDCpro-
duction of AM with healthy controls. In the present
study, we first reported that the spontaneousproduction
of MDC frompatients with IEPwas significantly higher
than that of HV, strongly indicating that AM in IEP
were stimulated by unknown stimuli to induce MDC
production in vivo. However, there is a possibility that
other cells in the lung play a role in the increased level
of MDC in BALF of patients with IEP. In particular,
DCs would be candidate forMDCproducer cells since
they have a much higher ability to produceMDC, al-
though the number ofDCs in the lung ismuch less (28).
Accordingly, our results suggest thatMDC produced
by AM could be involved in the pathogenesis of IEP,
although the possibility that DCs play a role in MDC
production in the lung still remains.
On the other hand, we did not detect any correlation
between the level of MDC or TARC and the number of
lymphocytes and eosinophils. Although Bochner et al.
reported that MDC also had the direct chemotactic
activity on eosinophils (31), the activity ofMDCorTARC
in the recruitment of eosinophils to the lung is presum-
ably due to the indirect effects of secondary factorswhich
might be produced by Th2 lymphocytes attracted and
activated byMDC. In fact, IL-5, which is known to be
produced by Th2 cells, is directly involved in the re-
cruitment of eosinophils in the lung (5).
In summary,MDC aswell as TARCwas significantly
elevated inBALFofpatientswith IEP.AMin IEPpatients
could produceahigher amountofMDCwhencompared
with HV. These results suggest that AMplay a crucial
role in Th2-type immune response in the pathogenesis
of IEP via enhanced MDC production.
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